-$1.39 Earnings Per Share Expected for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) This Quarter

Analysts predict that Arcutis Biotherapeutics, Inc. (NASDAQ:ARQTGet Rating) will report earnings of ($1.39) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Arcutis Biotherapeutics’ earnings. The lowest EPS estimate is ($1.43) and the highest is ($1.34). Arcutis Biotherapeutics posted earnings per share of ($0.84) in the same quarter last year, which suggests a negative year-over-year growth rate of 65.5%. The business is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Arcutis Biotherapeutics will report full-year earnings of ($5.74) per share for the current year, with EPS estimates ranging from ($6.21) to ($5.48). For the next financial year, analysts forecast that the business will report earnings of ($4.16) per share, with EPS estimates ranging from ($5.08) to ($3.44). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Arcutis Biotherapeutics.

Arcutis Biotherapeutics (NASDAQ:ARQTGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.15.

ARQT has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 23rd. Morgan Stanley boosted their price objective on shares of Arcutis Biotherapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, March 2nd. Zacks Investment Research upgraded shares of Arcutis Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 26th. The Goldman Sachs Group started coverage on shares of Arcutis Biotherapeutics in a research report on Thursday, March 17th. They set a “buy” rating and a $45.00 target price for the company. Finally, Mizuho lowered their price objective on shares of Arcutis Biotherapeutics from $58.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, April 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $41.50.

Shares of Arcutis Biotherapeutics stock traded up $0.56 during trading hours on Tuesday, reaching $21.11. The company’s stock had a trading volume of 267 shares, compared to its average volume of 398,623. Arcutis Biotherapeutics has a one year low of $13.59 and a one year high of $29.37. The company has a market capitalization of $1.09 billion, a P/E ratio of -4.49 and a beta of 0.28. The stock’s fifty day simple moving average is $20.20 and its two-hundred day simple moving average is $18.14. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.89 and a current ratio of 10.89.

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 7,500 shares of the stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $20.02, for a total transaction of $150,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Masaru Matsuda sold 1,795 shares of the firm’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $19.73, for a total transaction of $35,415.35. Following the completion of the transaction, the senior vice president now directly owns 16,380 shares of the company’s stock, valued at $323,177.40. The disclosure for this sale can be found here. Insiders sold a total of 551,996 shares of company stock worth $11,417,359 in the last quarter. Company insiders own 39.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in ARQT. Allspring Global Investments Holdings LLC purchased a new stake in shares of Arcutis Biotherapeutics during the fourth quarter worth about $12,809,000. Thrivent Financial for Lutherans acquired a new position in shares of Arcutis Biotherapeutics during the 3rd quarter worth approximately $248,000. Altium Capital Management LP increased its position in shares of Arcutis Biotherapeutics by 10.2% during the third quarter. Altium Capital Management LP now owns 255,000 shares of the company’s stock worth $6,092,000 after purchasing an additional 23,686 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Arcutis Biotherapeutics by 32.7% during the fourth quarter. Point72 Asset Management L.P. now owns 2,644,177 shares of the company’s stock worth $54,840,000 after purchasing an additional 652,070 shares in the last quarter. Finally, Martingale Asset Management L P purchased a new stake in shares of Arcutis Biotherapeutics during the third quarter worth approximately $282,000. Hedge funds and other institutional investors own 87.59% of the company’s stock.

About Arcutis Biotherapeutics (Get Rating)

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Further Reading

Get a free copy of the Zacks research report on Arcutis Biotherapeutics (ARQT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcutis Biotherapeutics (NASDAQ:ARQT)

Want More Great Investing Ideas?

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.